KOINOBORI Profile
Origin of the Name
Koinobori, carp-shaped wind socks that flap majestically in the blue skies over Japan during May, are symbols of the healthy growth of children and the happiness of families. Our organization, KOINOBORI, was named after these carp-shaped wind socks, as they reminded us of the patients and families who are fighting against rare and neglected difficult diseases.
Objectives and Background of Establishment
The demographic distribution of patients with rare and neglected diseases is not well known, and the mechanisms of such maladies are not well understood. Therefore, constant drug development for rare diseases is difficult, and
KOINOBORI is a nonprofit organization dedicated to bringing together accumulated knowledge and expertise for the development of new, concrete therapies that arrest disease progression and promote functional recovery in patients with mitochondrial diseases. Our team members include medical doctors, venture capitalists, academic researchers, patients' families, and scientists. KOINOBORI focuses on mitochondrial
Activities
In the treatment of mitochondrial diseases, promising new drugs and therapies are required for medical care, but steady improvements and lifestyle habits (diet, mental and physical activities, supplements, etc.) are also important. KOINOBORI aims to develop therapeutic drugs and form patient networks as its two main
- Drug Research and Development Support Program
- 1. Exploration of promising developmental compounds and therapy
2. Support for clinical developmental work
Research Ethics Committee
HISTORY
| 2009 | KOINOBORI started its activities. As a nonprofit, we began to examine ways to provide support for drug discovery for rare and neglected diseases. Because a family member of one of our members developed a mitochondrial disease, we began focusing on mitochondrial diseases, among other rare and neglected |
|---|---|
| 2010 | We began regular activities as the KOINOBORI project within PRIP TOKYO, a non-profit organization for the Promotion of Research on Intellectual Property, in April. As a drug research and development |
| 2011 | KOINOBORI began tangible support for clinical studies in Japan. |
| 2013 | We established KOINOBORI Associate Inc. in January. KOINOBORI initiated the clinical study of the supported compound in Japan in May. KOINOBORI became affiliated with the United Mitochondrial Disease Foundation (UMDF) as a part of the Patient Network-Forming Program (June). |
TEAM
Members
President : Masashi SUGANUMA (President, Suganuma Medical Clinic)Director : Taro INABA (Managing Partner, Remiges Biopharma Fund GP, Inc.)Director : Kinji FUCHIKAMI (Venture partner, Mitsui & Co. Global Investment, Inc.)Auditor : Eisaku NAKAMURA (Director, Kubota Pharmaceutical Holdings Co., Ltd. / Director, D. Western Therapeutics Institute, Inc.)
Basic Information
| Name | KOINOBORI Associate Inc. |
|---|---|
| Representative | Masashi Suganuma |
| Location | 1-1-16, Shibuya-cho, Toyota-shi, Aichi-ken 471-0808 Japan |
| Contact |  |
| Date of Establishment | January 17, 2013 |